{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:47:00Z","timestamp":1787647620836,"version":"build-2736575974"},"update-to":[{"DOI":"10.1002\/14651858.cd008766.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T00:00:00Z","timestamp":1657584000000}}],"reference-count":106,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008766.pub3","type":"journal-article","created":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T07:46:45Z","timestamp":1658735205000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer"],"prefix":"10.1002","volume":"2022","author":[{"given":"Aashna","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Natural Sciences; Middlesex University; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshni","family":"Kalachand","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology; Beaumont Hospital and Royal College of Surgeons in Ireland; Dublin 9 Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Busschots","sequence":"additional","affiliation":[{"name":"Department of Histopathology; St James Hospital and Trinity College Dublin; Dublin 8 Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Doherty","sequence":"additional","affiliation":[{"name":"Department of Histopathology; St James Hospital and Trinity College Dublin; Dublin 8 Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Kapros","sequence":"additional","affiliation":[{"name":"Department of Computer Science; Trinity College Dublin; Dublin 2 Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Lawlor","sequence":"additional","affiliation":[{"name":"Department of Histopathology; St James Hospital and Trinity College Dublin; Dublin 8 Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neville","family":"Hall","sequence":"additional","affiliation":[{"name":"Department of Natural Sciences; Middlesex University; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta K","family":"Stordal","sequence":"additional","affiliation":[{"name":"Department of Natural Sciences; Middlesex University; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,7,12]]},"reference":[{"key":"10.1002\/14651858.CD008766.pub3-BIB0001|cit1","doi-asserted-by":"crossref","unstructured":"Eisenhauer E Bacon M Walsh W McDaniel C Canetta R Onetto N Long term survivors from a European-Canadian trial of paclitaxel in platinum-pretreated ovarian cancer (OVCA) European Cancer Conference; 1997 1997 Abstract 532","DOI":"10.1016\/S0959-8049(97)85045-9"},{"issue":"12","key":"10.1002\/14651858.CD008766.pub3-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1200\/jco.1994.12.12.2654","article-title":"European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion","volume":"12","author":"Eisenhauer","year":"1994","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD008766.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0305-7372(93)90050-2","article-title":"Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer","volume":"19 Suppl C","author":"Ten Bokkel Huinink","year":"1993","journal-title":"Cancer Treatment Reviews"},{"key":"10.1002\/14651858.CD008766.pub3-BIB0004|cit4","first-page":"280, Abstract 7","article-title":"A randomized trial of paclitaxel (T) at 2 dose levels and filgrastim (G; G-CSF) at 2 doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): a Gynecologic Oncology Group, SWOG, NCCTG and ECOG study","volume":"15","author":"Omura","year":"1996","journal-title":"American Society of Clinical Oncology"},{"issue":"15","key":"10.1002\/14651858.CD008766.pub3-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1200\/JCO.2003.10.082","article-title":"Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study","volume":"21","author":"Omura","year":"2003","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008766.pub3-BIB0006|cit6","first-page":"35","article-title":"Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study","volume":"10","author":"Osman","year":"2016","journal-title":"Clinical Medicine Insights: Oncology"},{"key":"10.1002\/14651858.CD008766.pub3-BIB0007|cit7","unstructured":"Andersson H Boman K Ridderheim P Rosenberg P Sorbe U Puistola U An updated analysis of a randomised study of single agent paclitaxel (P) given weekly versus every 3 weeks to patients (Pts) with ovarian cancer (OV) treated with prior platinum therapy American Society of Clinical Oncology; 2000 2000"},{"issue":"5 CNO","key":"10.1002\/14651858.CD008766.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1080\/028418602320404998","article-title":"Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum","volume":"41","author":"Rosenberg","year":"2002","journal-title":"Acta Oncologica (Stockholm, Sweden)"},{"issue":"5","key":"10.1002\/14651858.CD008766.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1200\/JCO.2002.20.5.1232","article-title":"Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens","volume":"20","author":"Cantu","year":"2002","journal-title":"Journal of Clinical Oncology"},{"issue":"18 Suppl","key":"10.1002\/14651858.CD008766.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1200\/jco.2007.25.18_suppl.5505","article-title":"Final results of After-6 protocol 1: a phase III trial of observation versus 6 courses of paclitaxel (Pac) in advanced ovarian cancer patients in complete response (CR) after platinum-paclitaxel chemotherapy (CT)","volume":"25","author":"Conte","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD008766.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0959-8049(97)89009-0","article-title":"Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with platinum","volume":"33","author":"Du Bois","year":"1997","journal-title":"European Journal of Cancer"},{"issue":"28","key":"10.1002\/14651858.CD008766.pub3-BIB0012|cit12","first-page":"4642","article-title":"Randomized phase III trial of observation versus 6 courses of single agent paclitaxel in patients with advanced ovarian cancer who attained a complete response to platinum-paclitaxel based chemotherapy. An Italian study (AFTER-6 protocol 1)","volume":"27","author":"Favalli","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008766.pub3-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1200\/jco.1993.11.11.2127","article-title":"Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients","volume":"11","author":"Huizing","year":"1993","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008766.pub3-BIB0014|cit14","first-page":"446 Abstract no","article-title":"Randomized trial of paclitaxel in combination with platinum chemotherapy versus platinum\/based chemotherapy in the treatment of relapsed ovarian cancer (ICON4\/OVAR 2.2)","author":"Ledermann","year":"2003","journal-title":"American Society of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD008766.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1200\/JCO.2002.09.130","article-title":"Phase II trial of weekly single-agent paclitaxel in platinum\/paclitaxel-refractory ovarian cancer","volume":"20","author":"Markman","year":"2002","journal-title":"Journal of Clinical Oncology"},{"issue":"13","key":"10.1002\/14651858.CD008766.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2003.07.013","article-title":"Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial","volume":"21","author":"Markman","year":"2003","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD008766.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1006\/gyno.1996.4514","article-title":"Taxol as second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy","volume":"64","author":"Mayerhofer","year":"1997","journal-title":"Gynecologic Oncology"},{"issue":"3","key":"10.1002\/14651858.CD008766.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/00000421-199706000-00003","article-title":"Paclitaxel as salvage therapy in advanced pretreated ovarian cancer: a phase II study","volume":"20","author":"Nardi","year":"1997","journal-title":"American Journal of Clinical Oncology"},{"issue":"28","key":"10.1002\/14651858.CD008766.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2009.21.9691","article-title":"Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel\/platinum-based chemotherapy: final results of the After-6 protocol","volume":"27","author":"Pecorelli","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD008766.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1200\/JCO.2000.18.6.1193","article-title":"Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology group","volume":"18","author":"Piccart","year":"2000","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD008766.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ygyno.2006.10.006","article-title":"Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel-ANZGOG 02-01","volume":"104","author":"Tinker","year":"2007","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD008766.pub3-BIB0022|cit22","first-page":"381a, Abstract","article-title":"Randomized trial comparing paclitaxel + doxorubicin (AT) versus paclitaxel (T) as second line therapy for advanced ovarian cancer (AOC) patients in early progression after platinum based chemotherapy","volume":"19","author":"Torri","year":"2000","journal-title":"American Society of Clinical Oncology (proceedings)"},{"issue":"12","key":"10.1002\/14651858.CD008766.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1023\/A:1008400324892","article-title":"Long-term results from a phase II study of single agent paclitaxel (taxol) in previously platinum treated patients with advanced ovarian cancer: the Nordic experience","volume":"9","author":"Trope","year":"1998","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD008766.pub3-BIB0024|cit24","volume-title":"Molecular Biology of the Cell","author":"Alberts","year":"2002"},{"issue":"4","key":"10.1002\/14651858.CD008766.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1046\/j.1525-1438.1997.00449.x","article-title":"Taxol given weekly in advanced previously treated ovarian carcinomas - a pilot study","volume":"7","author":"Andersson","year":"1997","journal-title":"International Journal of Gynecological Cancer"},{"issue":"5","key":"10.1002\/14651858.CD008766.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1159\/000227586","article-title":"Salvage chemotherapy with paclitaxel in platinum-resistant advanced ovarian cancer patients","volume":"53","author":"Bruzzone","year":"1996","journal-title":"Oncology"},{"key":"10.1002\/14651858.CD008766.pub3-BIB0027|cit27","unstructured":"Cancer Research UK Cancer incidence statistics cancerresearchuk.org\/health-professional\/cancer-statistics\/incidence"},{"issue":"3","key":"10.1002\/14651858.CD008766.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The functional assessment of cancer therapy scale: development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"Journal of Clinical Oncology\u00a0"},{"issue":"8","key":"10.1002\/14651858.CD008766.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1056\/NEJMoa1505067","article-title":"Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer","volume":"374","author":"Chan","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"10214","key":"10.1002\/14651858.CD008766.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/S0140-6736(19)32259-7","article-title":"Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial","volume":"394","author":"Clamp","year":"2019","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008766.pub3-BIB0031|cit31","unstructured":"Covidence Systematic Review Software Veritas Health Innovation 2020"},{"issue":"1","key":"10.1002\/14651858.CD008766.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5528\/wjtm.v3.i1.1","article-title":"Epithelial ovarian cancer: an overview","volume":"3","author":"Desai","year":"2014","journal-title":"World Journal of Translational Medicine"},{"issue":"4","key":"10.1002\/14651858.CD008766.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1634\/theoncologist.1-4-240","article-title":"The clinical development of paclitaxel: a successful collaboration of academia, industry and the National Cancer Institute","volume":"1","author":"Donehower","year":"1996","journal-title":"Oncologist"},{"issue":"1","key":"10.1002\/14651858.CD008766.pub3-BIB0034|cit34","first-page":"79","article-title":"Preliminary experience with salvage weekly paclitaxel in women with advanced recurrent ovarian carcinoma","volume":"26","author":"Dunder","year":"2005","journal-title":"European Journal of Gynaecological Oncology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD008766.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"v61","DOI":"10.1093\/annonc\/mdg754","article-title":"EUROCARE-3: survival of cancer patients diagnosed 1990\u201394 \u2013 results and commentary","volume":"14","author":"Sant","year":"2003","journal-title":"Annals of Oncology"},{"issue":"5 Suppl 15","key":"10.1002\/14651858.CD008766.pub3-BIB0036|cit36","first-page":"S15","article-title":"Paclitaxel in platinum-resistant ovarian cancer patients.","volume":"24","author":"Ezcurdia","year":"1997","journal-title":"Seminars in Oncology"},{"issue":"1","key":"10.1002\/14651858.CD008766.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/JCO.1997.15.1.187","article-title":"Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer","volume":"15","author":"Fennelly","year":"1997","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD008766.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/ijc.33588","article-title":"Cancer statistics for the year 2020: an overview","volume":"149","author":"Ferlay","year":"2021","journal-title":"International Journal of Cancer"},{"issue":"4","key":"10.1002\/14651858.CD008766.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/IGC.0b013e31821bb8aa","article-title":"Clinical trials in recurrent ovarian cancer","volume":"21","author":"Friedlander","year":"2011","journal-title":"International Journal of Gynecological Cancer"},{"issue":"2","key":"10.1002\/14651858.CD008766.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/ijgc-00009577-200303000-00007","article-title":"Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer","volume":"13","author":"Ghamande","year":"2003","journal-title":"International Journal of Gynecological Cancer"},{"issue":"1","key":"10.1002\/14651858.CD008766.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1200\/JCO.1995.13.1.180","article-title":"Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic\/pharmacodynamic relationships in humans","volume":"13","author":"Gianni","year":"1995","journal-title":"Journal of Clinical Oncology"},{"issue":"S2","key":"10.1002\/14651858.CD008766.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/theoncologist.9-suppl_2-3","article-title":"Preclinical pharmacology of the taxanes: implications of the differences","volume":"9","author":"Gligorov","year":"2004","journal-title":"Oncologist"},{"issue":"4","key":"10.1002\/14651858.CD008766.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/bjc.1995.453","article-title":"Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience","volume":"72","author":"Gore","year":"1995","journal-title":"British Journal of Cancer"},{"issue":"6","key":"10.1002\/14651858.CD008766.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/bjc.1995.253","article-title":"Platinum-taxol non-cross resistance in epithelial ovarian cancer","volume":"71","author":"Gore","year":"1995","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD008766.pub3-BIB0045|cit45","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2015"},{"issue":"1","key":"10.1002\/14651858.CD008766.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ijc.10907","article-title":"Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere)","volume":"104","author":"Grant","year":"2003","journal-title":"International Journal of Cancer"},{"issue":"10","key":"10.1002\/14651858.CD008766.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1097\/CAD.0000000000000279","article-title":"Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy","volume":"26","author":"Hashiguchi","year":"2015","journal-title":"Anticancer Drugs"},{"issue":"3","key":"10.1002\/14651858.CD008766.pub3-BIB0048|cit48","first-page":"249","article-title":"Chemotherapy resistance of ovarian cancer patients after platinum-based therapy paclitaxel as a choice of treatment. [Hungarian]","volume":"64","author":"Hernadi","year":"2001","journal-title":"Magyar Noorvosok Lapja"},{"key":"10.1002\/14651858.CD008766.pub3-BIB0049|cit49","unstructured":"Higgins JPT Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"6","key":"10.1002\/14651858.CD008766.pub3-BIB0050|cit50","first-page":"272","article-title":"[Favorable results of paclitaxel (taxol) in patients with ovary carcinoma pretreated with platinum] [Dutch]","volume":"139","author":"Hoekman","year":"1995","journal-title":"Nederlands Tijdschrift voor Geneeskunde"},{"issue":"1","key":"10.1002\/14651858.CD008766.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/01.coc.0000045849.95834.6B","article-title":"Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: case-control analysis of toxicity","volume":"27","author":"Hsu","year":"2004","journal-title":"American Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD008766.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/PL00012094","article-title":"3-hour infusion of single-agent paclitaxel for recurrent ovarian cancer","volume":"6","author":"Ishikawa","year":"2001","journal-title":"International Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD008766.pub3-BIB0053|cit53","first-page":"71","article-title":"Cancer statistics","volume":"58","author":"Jemal","year":"2008","journal-title":"CA: a Cancer Journal for Clinicians"},{"key":"10.1002\/14651858.CD008766.pub3-BIB0054|cit54","first-page":"69","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA: a Cancer Journal for Clinicians"},{"issue":"4","key":"10.1002\/14651858.CD008766.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrc1317","article-title":"Microtubules as a target for anticancer drugs","volume":"4","author":"Jordan","year":"2004","journal-title":"Nature Reviews. Cancer"},{"issue":"5","key":"10.1002\/14651858.CD008766.pub3-BIB0056|cit56","first-page":"383","article-title":"A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients","volume":"23","author":"Kaern","year":"2002","journal-title":"European Journal of Gynaecological Oncology"},{"issue":"10","key":"10.1002\/14651858.CD008766.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S1470-2045(13)70363-2","article-title":"Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial","volume":"14","author":"Katsumata","year":"2013","journal-title":"Lancet Oncology"},{"issue":"3","key":"10.1002\/14651858.CD008766.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.ygyno.2003.12.002","article-title":"The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer","volume":"92","author":"Kita","year":"2004","journal-title":"Gynecologic Oncology"},{"issue":"1","key":"10.1002\/14651858.CD008766.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/jnci\/86.1.18","article-title":"Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer","volume":"86","author":"Kohn","year":"1994","journal-title":"Journal of the National Cancer Institute"},{"issue":"Suppl","key":"10.1002\/14651858.CD008766.pub3-BIB0060|cit60","article-title":"Chemotherapy versus hormonal treatment in patients with platinum and taxane resistant ovarian cancer: a NSGO study","volume":"26","author":"Kristensen","year":"2008","journal-title":"Journal of Clinical Oncology (ASCO Annual Meeting Proceedings)"},{"issue":"1","key":"10.1002\/14651858.CD008766.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1046\/j.1525-1438.1999.09856.x","article-title":"Long-term results and pharmacokinetics of high-dose paclitaxel in patients with refractory epithelial ovarian carcinoma","volume":"9","author":"Kudelka","year":"1999","journal-title":"International Journal of Gynaecological Cancer"},{"key":"10.1002\/14651858.CD008766.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/2046-4053-2-81","article-title":"Assessing and presenting summaries of evidence in Cochrane Reviews","volume":"2","author":"Langendam","year":"2013","journal-title":"Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD008766.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ygyno.2005.11.025","article-title":"Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer","volume":"102","author":"Le","year":"2006","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD008766.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLOS Medicine"},{"issue":"3","key":"10.1002\/14651858.CD008766.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nrclinonc.2016.195","article-title":"RECIST - learning from the past to build the future","volume":"14","author":"Liti\u00e8re","year":"2017","journal-title":"Nature Reviews. Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD008766.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/annonc\/mdr149","article-title":"Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO)","volume":"23","author":"Lortholary","year":"2012","journal-title":"Annals of Oncology"},{"issue":"3","key":"10.1002\/14651858.CD008766.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ygyno.2005.10.036","article-title":"Phase II trial of weekly paclitaxel (80 mg\/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study","volume":"101","author":"Markman","year":"2006","journal-title":"Gynecologic Oncology"},{"issue":"4","key":"10.1002\/14651858.CD008766.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"273","DOI":"10.7326\/0003-4819-111-4-273","article-title":"Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms","volume":"111","author":"McGuire","year":"1989","journal-title":"Annals of Internal.Medicine"},{"issue":"1","key":"10.1002\/14651858.CD008766.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008766.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/2046-4053-3-82","article-title":"A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation","volume":"3","author":"Meader","year":"2014","journal-title":"Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD008766.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00404-016-4035-8","article-title":"The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications","volume":"293","author":"Meinhold-Heerlein","year":"2016","journal-title":"Archives of Gynecology and Obstetrics"},{"key":"10.1002\/14651858.CD008766.pub3-BIB0072|cit72","unstructured":"Territo M Neutropenia - Hematology and Oncology MSD Manual Professional Version. Available from www.msdmanuals.com\/en-gb\/professional\/hematology-and-oncology\/leukopenias\/neutropenia"},{"key":"10.1002\/14651858.CD008766.pub3-BIB0073|cit73","unstructured":"Guidance on the use of paclitaxel in the treatment of ovarian cancer: Technology appraisal guidance [TA55] Published date: 22 January 2003 Last updated: 01 May 2005 www.nice.org.uk\/guidance\/ta55"},{"key":"10.1002\/14651858.CD008766.pub3-BIB0074|cit74","unstructured":"Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer: Technology appraisal guidance [TA389] www.nice.org.uk\/guidance\/ta389"},{"key":"10.1002\/14651858.CD008766.pub3-BIB0075|cit75","unstructured":"Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer. Technology appraisal guidance [TA620] www.nice.org.uk\/guidance\/ta620"},{"issue":"14","key":"10.1002\/14651858.CD008766.pub3-BIB0076|cit76","first-page":"2461","article-title":"[A phase II study of BMS-181339 in patients with ovarian cancer] [Japanese]","volume":"21","author":"Noda","year":"1994","journal-title":"Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]"},{"issue":"3","key":"10.1002\/14651858.CD008766.pub3-BIB0077|cit77","first-page":"317","article-title":"[Phase II study of paclitaxel (BMS-181339) in patients with ovarian cancer by 3-hour intravenous infusion] [Japanese]","volume":"23","author":"Noda","year":"1996","journal-title":"Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]"},{"issue":"4","key":"10.1002\/14651858.CD008766.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1179\/joc.1999.11.4.301","article-title":"Paclitaxel efficacy and tolerability in second-line treatment of refractory and relapsed ovarian cancer patients","volume":"11","author":"Oliverio","year":"1999","journal-title":"Journal of Chemotherapy"},{"issue":"2 Suppl 6","key":"10.1002\/14651858.CD008766.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.seminoncol.2006.03.011","article-title":"Systemic therapy for ovarian cancer: current status and new treatments","volume":"33","author":"Ozols","year":"2006","journal-title":"Seminars in Oncology"},{"issue":"10","key":"10.1002\/14651858.CD008766.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/jjco\/hyg093","article-title":"Measuring response in solid tumors: comparison of RECIST and WHO response criteria","volume":"33","author":"Park","year":"2003","journal-title":"Japanese Journal of Clinical Oncology"},{"issue":"24","key":"10.1002\/14651858.CD008766.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"3","key":"10.1002\/14651858.CD008766.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1159\/000011856","article-title":"Paclitaxel in cisplatin or carboplatin-pretreated ovarian cancer. Phase II study","volume":"55","author":"Pectasides","year":"1998","journal-title":"Oncology"},{"issue":"4","key":"10.1002\/14651858.CD008766.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1445-5994.1995.tb01899.x","article-title":"Australasian multicentre phase II study of paclitaxel (taxol) in relapsed ovarian cancer","volume":"25","author":"Phillips","year":"1995","journal-title":"Australian and New Zealand Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD008766.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S1470-2045(15)70115-4","article-title":"Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial","volume":"16","author":"Pignata","year":"2015","journal-title":"Lancet Oncology"},{"issue":"2","key":"10.1002\/14651858.CD008766.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1479-828X.1996.tb03278.x","article-title":"Paclitaxel (taxol) as salvage therapy for relapsed ovarian cancer","volume":"36","author":"Planner","year":"1996","journal-title":"Australian & New Zealand Journal of Obstetrics & Gynaecology"},{"key":"10.1002\/14651858.CD008766.pub3-BIB0086|cit86","unstructured":"Review Manager 5 (RevMan 5) Nordic Cochrane Centre, The Cochrane Collaboration 2022"},{"issue":"7","key":"10.1002\/14651858.CD008766.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1200\/JCO.1992.10.7.1165","article-title":"Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer","volume":"10","author":"Sarosy","year":"1992","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008766.pub3-BIB0088|cit88","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, (editors).\u00a0 Cochrane Handbook for Systematic Reviews of Interventions \u00a0Version 6.1\u00a0(updated September 2020). Cochrane, 2020 Available from training.cochrane.org\/handbook\/current\/chapter-14"},{"issue":"12","key":"10.1002\/14651858.CD008766.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/0021-9681(81)90058-8","article-title":"Measuring the quality of life of cancer patients: a concise QL-index for use by physicians","volume":"34","author":"Spitzer","year":"1981","journal-title":"Journal of Chronic Diseases"},{"issue":"8","key":"10.1002\/14651858.CD008766.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.ctrv.2007.07.013","article-title":"A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship","volume":"33","author":"Stordal","year":"2007","journal-title":"Cancer Treatment Reviews"},{"issue":"4","key":"10.1002\/14651858.CD008766.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ctrv.2007.01.009","article-title":"Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review","volume":"33","author":"Stordal","year":"2007","journal-title":"Cancer Treatment Reviews"},{"issue":"11","key":"10.1002\/14651858.CD008766.pub3-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1080\/15216540701636287","article-title":"Understanding cisplatin resistance using cellular models","volume":"59","author":"Stordal","year":"2007","journal-title":"International Union of Biochemistry & Molecular Biology Life"},{"issue":"3","key":"10.1002\/14651858.CD008766.pub3-BIB0093|cit93","first-page":"1833","article-title":"Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer","volume":"22","author":"Takano","year":"2002","journal-title":"Anticancer Research"},{"issue":"6","key":"10.1002\/14651858.CD008766.pub3-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.1997.15.6.2183","article-title":"Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer","volume":"15","author":"Ten Bokkel Huinink","year":"1997","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD008766.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1994.12.9.1748","article-title":"Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study","volume":"12","author":"Thigpen","year":"1994","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD008766.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"12","key":"10.1002\/14651858.CD008766.pub3-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1200\/JCO.1993.11.12.2405","article-title":"Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103","volume":"11","author":"Trimble","year":"1993","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD008766.pub3-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Seminars in Radiation Oncology"},{"issue":"1","key":"10.1002\/14651858.CD008766.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1089\/152581602753448577","article-title":"Docetaxel versus paclitaxel for antiangiogenesis","volume":"11","author":"Vacca","year":"2002","journal-title":"Journal of Hematotherapy & Stem Cell Research"},{"issue":"1","key":"10.1002\/14651858.CD008766.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/his.12046","article-title":"Fallopian tube precursors of ovarian low- and high-grade serous neoplasms","volume":"62","author":"Vang","year":"2013","journal-title":"Histopathology"},{"issue":"22","key":"10.1002\/14651858.CD008766.pub3-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/jnci\/djh323","article-title":"Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma","volume":"96","author":"Vasey","year":"2004","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD008766.pub3-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/ijgc-00009577-200107001-00006","article-title":"The integration of paclitaxel and new platinum compounds in the treatment of advanced ovarian cancer","volume":"11 Suppl 1","author":"Vermorken","year":"2001","journal-title":"International Journal of Gynecological Cancer"},{"issue":"6","key":"10.1002\/14651858.CD008766.pub3-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/oxfordjournals.annonc.a058903","article-title":"Paclitaxel (taxol) and docetaxel (taxotere): not simply two of a kind","volume":"5","author":"Verweij","year":"1994","journal-title":"Annals of Oncology"},{"issue":"6","key":"10.1002\/14651858.CD008766.pub3-BIB0104|cit104","first-page":"610","article-title":"Phase II study of high-dose paclitaxel in platinum-refractory epithelial ovarian cancer","volume":"21","author":"Wilailak","year":"2000","journal-title":"European Journal of Gynaecological Oncology"},{"issue":"5","key":"10.1002\/14651858.CD008766.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00404-014-3364-8","article-title":"The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer","volume":"290","author":"Zeppernick","year":"2014","journal-title":"Archives of Gynecology and Obstetrics"},{"issue":"10","key":"10.1002\/14651858.CD008766.pub3-BIB0106|cit106","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008766","article-title":"Taxane monotherapy for the treatment of platinum pre-treated epithelial ovarian cancer","author":"Stordal","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T06:33:44Z","timestamp":1735799624000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD008766.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,7,12]]},"references-count":106,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008766.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,12]]}}}